Remy Luthringer
Principal executive officer pay for Remy Luthringer, by year and company, from pay-versus-performance disclosure. Every figure links to its source on the company page.
Minerva Neurosciences, Inc. (NERV) FY2022–FY2025
Aligned: paid up as stock roseCAP $1,283,412→$9,858,784 while $100 invested went $24.80→$252.83
| Fiscal year | SCT total | Comp actually paid |
|---|---|---|
| FY2022 | $1.3M | $1.3M |
| FY2023 | $1.8M | $2.1M |
| FY2024 | $1.2M | $1.3M |
| FY2025 | $9.4M | $9.9M |
The company's "$100 invested" index ran $24.80 at FY2022 → $252.83 by FY2025 — an annualized return of 116.8%.
Track record
1 measurable tenure in the pay-versus-performance disclosure window. Best annualized TSR: 116.8%/yr at NERV ( FY2022–FY2025). See the CEO track-record ranking for context.